Patent application number | Description | Published |
20100225303 | METHOD AND DEVICE FOR MULTICHANNEL MULTIFREQUENCY ANALYSIS OF AN OBJECT - A method for multichannel multifrequency analysis of an object, applying a set of excitation signals to the object and sampling the response signal from the object, using uniform and non-uniform undersampling. Non-uniform sampling of the response signal is performed, i.e., the sampling is performed for two or more different frequencies in one observation time slot. Also, uniform sampling of the response signal is performed, i.e., the sampling of a signal, corresponding to one frequency, is performed for two or more channels within one observation time slot and then sampling the same signal for another frequency for two or more channels within the next observation time slot. | 09-09-2010 |
20110074442 | METHOD AND DEVICE USING SHORTENED SQUARE WAVE WAVEFORMS IN SYNCHRONOUS SIGNAL PROCESSING - A method for impedance measurements, using synchronous detecting and modified rectangular signals. The method comprises introducing a first modified rectangular signal into a bioobject, receiving a response signal from said bioobject, introducing said response signal and a second modified rectangular signal into a synchronous detector, whereas either one or both rectangular signals are modified to remove particular higher harmonics from the signal. In one embodiment, either one or both the first and the second modified rectangular signals are generated by summing at least two modified rectangular signals, wherein at least one of such rectangular signals have a zero amplitude segment introduced between rectangular half periods. | 03-31-2011 |
20110095747 | METHOD AND DEVICE FOR FAST MEASUREMENT OF FREQUENCY RESPONSE WITH SCALABLE SHORT CHIRP SIGNALS - A method and device are provided for fast impedance measurement of a biological object having dynamically varying in time parameters, wherein a titlet shaped pulse is introduced into the object and a voltage response signal is measured and analyzed by a processing unit for estimating the impedance of the object. The titlet pulse has a start frequency substantially in one end of the frequency range of interest and a stop frequency substantially in the other end of the frequency range of interest and a duration of the titlet pulse is one cycle or less. | 04-28-2011 |
20120007583 | METHOD AND DEVICE FOR FREQUENCY RESPONSE MEASUREMENT - A method is provided for measuring a frequency response of an object, the method involving: generating an excitation signal having relatively fast changing frequency, defined by a time-domain function; generating at least one reference signal, having a waveform corresponding to the excitation signal; introducing the excitation signal into the object, receiving a response signal from the object; analyzing said response signal in a signal analyzer by correlating the response signal with at least one reference signal during a relatively short sliding time-domain window. | 01-12-2012 |
20130054178 | METHOD AND DEVICE FOR BROADBAND ANALYSIS OF SYSTEMS AND SUBSTANCES - A method and device for high speed broadband testing of systems and substances using a binary, spectrally sparse sequence (SSS) as a periodic excitation waveform. The sequences with controllable frequency and magnitude spectra content are designed by component manipulation method or by edge manipulation method. The excitation waveform is typically pre-calculated, and kept in waveform memory, from where it is shifted out into digital to physical quantity converter (DQC). | 02-28-2013 |
20140323903 | METHOD AND DEVICE FOR MULTICHANNEL MULTIFREQUENCY ANALYSIS OF AN OBJECT - A method for multichannel multifrequency analysis of an object, applying a set of excitation signals to the object and sampling the response signal from the object, using uniform and non-uniform undersampling. Non-uniform sampling of the response signal is performed, i.e., the sampling is performed for two or more different frequencies in one observation time slot. Also, uniform sampling of the response signal is performed, i.e., the sampling of a signal, corresponding to one frequency, is performed for two or more channels within one observation time slot and then sampling the same signal for another frequency for two or more channels within the next observation time slot. | 10-30-2014 |
Patent application number | Description | Published |
20090136016 | Transferring a communication event - A method of transferring a communication event from a calling user to at least one destination user is provided. The method comprises a communication client of the calling user establishing a connection with a communication client of an intermediate user over a packet-based communication network, the intermediate user selecting to transfer the connection to the at least one destination user by actuating a control displayed in the communication client of the intermediate user, the communication client of the intermediate user transmitting a message to the communication client of the calling user comprising at least one network identity of the at least one destination user, and the communication client of the calling user receiving the message and establishing a connection with a communication client of the at least one destination user using the network identity. | 05-28-2009 |
20110141925 | Measuring call quality - Provided is a method, computer program product, and apparatus for estimating the quality of a call in which a first user terminal will comprise an end point. The method comprises establishing an end-to-end connection between a first user terminal and a node, which end-to-end connection is via an access point of a network by which the first user terminal is connected to the network; displaying information indicative of an expected quality of a call in which the first user terminal will comprise an end point, in dependence on information indicative of the quality of the end-to-end connection; and providing call initiation means for enabling a user to then selectively establish a call between the first user terminal and a callee. Also provided is a method, computer program product, and apparatus for estimating the quality of a call between a first user terminal and a potential callee. | 06-16-2011 |
20120057683 | Call Re-Establishment - Method and user terminal for handling a call over a communications network between a first user terminal, usable by a first user, and at least one other user terminal, usable by a respective at least one other user, wherein a client is executed at the first user terminal for participation in the call. The client determines a condition of a respective at least one network connection used in the call between the first user terminal and the at least one other user terminal over the communications network. The client also determines that the call has been dropped, and responsive to the determination that the call has been dropped, the client automatically attempts to re-establish the call in dependence upon the determined condition of the at least one network connection. | 03-08-2012 |
20140029732 | Call Re-Establishment - Method and user terminal for handling a call over a communications network between a first user terminal, usable by a first user, and at least one other user terminal, usable by a respective at least one other user, wherein a client is executed at the first user terminal for participation in the call. The client determines a condition of a respective at least one network connection used in the call between the first user terminal and the at least one other user terminal over the communications network. The client also determines that the call has been dropped, and responsive to the determination that the call has been dropped, the client automatically attempts to re-establish the call in dependence upon the determined condition of the at least one network connection. | 01-30-2014 |
Patent application number | Description | Published |
20100199087 | SYSTEM AND METHOD FOR GENERATING A DIGITAL CERTIFICATE - A system and method for generating a digital certificate is provided wherein a new digital record is received and is assigned a sequence value. A first composite digital value is generated by applying a first deterministic function to the digital records stored in a repository. The sequence value and first composite digital value are included in a first certificate. After the digital record is added to the repository, a second composite digital value is generated by applying a second deterministic function to the digital records in the repository. This second composite digital value, and a composite sequence value, are published. An interval digital value which is based upon the first and second composite digital values, and the sequence value, are included in a second certificate which thus verifies the authenticity and sequence value of the digital record. | 08-05-2010 |
20100199342 | SYSTEM AND METHOD FOR GENERATING A DIGITAL CERTIFICATE - A system and method for generating a digital certificate is provided wherein a new digital record is received and is assigned a sequence value. A first composite digital value is generated by applying a first deterministic function to the digital records stored in a repository. The sequence value and first composite digital value are included in a first certificate. After the digital record is added to the repository, a second composite digital value is generated by applying a second deterministic function to the digital records in the repository. This second composite digital value, and a composite sequence value, are published. An interval digital value which is based upon the first and second composite digital values, and the sequence value, are included in a second certificate which thus verifies the authenticity and sequence value of the digital record. | 08-05-2010 |
20120324229 | SYSTEM AND METHOD FOR GENERATING KEYLESS DIGITAL MULTI-SIGNATURES - A method of generating a keyless digital multi-signature is provided. The method includes receiving multiple signature generation requests from one or more client computers, building subtrees based on the signature generation requests, and constructing a search tree including the subtrees. The method also includes assigning explicit length tags to leaf nodes of the search tree to balance the search tree and applying a hash function to each of the search tree nodes. The root hash value and the height of the search tree make up a generated aggregate signature request, followed by receiving an aggregate signature based on the aggregate signature request. The keyless digital multi-signature is generated based on the aggregate signature and contains an implicit length tag to verify that the number of signature generation requests is limited. The aggregate signature is generated if the height of the search tree does not exceed a predetermined height limitation. | 12-20-2012 |
20130276058 | DOCUMENT VERIFICATION WITH DISTRIBUTED CALENDAR INFRASTRUCTURE - Transformations of digital records are used as lowest level inputs to a tree data structure having a root in a core system and having nodes computed as digital combinations of child node values. A combination of root values is published in a permanent medium. Signature vectors are associated with the digital records and have parameters that enable recomputation upward through the tree data structure to either a current root value or to the published value. Recomputation yields the same value only if a candidate digital record is an exact version of the original digital record included in the original computation of the value. | 10-17-2013 |
20140282863 | Document Verification With Distributed Calendar Infrastructure - Transformations of digital records are used as lowest level inputs to a tree data structure having a root in a core system and having nodes computed as digital combinations of child node values. Signature vectors are associated with the digital records and have parameters that enable recomputation upward through the tree data structure to either a current calendar value or onward to a composite calendar value that is a function of calendar values in a calendar, which comprises a set of computed calendar values, such that the calendar values have a time correspondence. Recomputation yields the same value only if a candidate digital record is an exact version of the original digital record included in the original computation of the value, indicating authentication of the candidate digital record. The authentication process as such is independent of any trust authority that issues cryptographic keys. | 09-18-2014 |
20160028721 | Document Verification With Distributed Calendar Infrastructure - A client system is configured to obtain signatures for digital input records. An application program interface reformats each digital record, and this is used as an argument to a cryptographic hash function, from which a signature request is formed. The signature request is then submitted to a keyless, distributed hash tree infrastructure system, which returns a signature that includes recomputation values enabling recomputation from the result of the cryptographic hash function upward through the hash tree infrastructure to a root hash value at a calendar period corresponding to a time during which the signature request was originally submitted. An arbitrary subsequent test digital record is considered authenticated if, applying the cryptographic hash function to it, along with any other parameters included in the original computation, and recomputing an uppermost value using the recomputation values, the same composite calendar value is attained as when it was originally computed. | 01-28-2016 |
Patent application number | Description | Published |
20080269154 | Novel neurotrophic factor protein and uses thereof - The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is also a useful effector of primary and central neurons, especially dopaminergic neurons at the central nervous system and growth factor genes. | 10-30-2008 |
20090282495 | NEUROTROPHIC FACTOR MANF AND USES THEREOF - The present invention generally relates to the field of treatment of neuronal disorders and more particularly to neurotrophic factor MANF and uses thereof. The present invention provides a pharmaceutical compound comprising MANF nucleic acid molecule, MANF protein or a functional fragment thereof for the treatment of a peripherial neuropathy including Alzheimer's disease, Parkinson's disease, epilepsy, drug addiction and ischemic brain injury. | 11-12-2009 |
20100285045 | Novel Neurotrophic Factor Protein and Uses Thereof - The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is also a useful effector of primary and central neurons, especially dopaminergic neurons at the central nervous system and growth factor genes. | 11-11-2010 |
20110152346 | Use of Oligonucleotides with Modified Bases in Hybridization of Nucleic Acids - The invention is concerned with the use of oligonucleotide analogs that contain specifically modified DNA bases to be used in hybridization of nucleic acids, polymerase chain reaction (PCR) and siRNA-mediated gene silencing (RNAi). | 06-23-2011 |
20110171287 | Use of Oligonucleotides with Modified Bases as Antiviral Agents - The present invention relates to the use of oligonucleotides having modified nucleobases to inhibit gene expression and/or replication of viruses in a subject. The modified nucleobases may be mercapto-modified bases or hydroxy-modified nucleobases. It is contemplated that the oligonucleotides further comprise a nuclease complex which enhances anti-viral activity of the oligonucleotides. | 07-14-2011 |
20110251132 | TREATMENT WITH A PHARMACEUTICAL COMPOSITION COMPRISING MANF2 NUCLEIC ACID - A method for treating a condition in a patient, wherein the condition is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, stroke and peripheral neuropathy. The method consists of administering to the patient a pharmaceutically effective amount of a pharmaceutical composition comprising the MANF2 polypeptide of SEQ ID NO:2 or a functional fragment thereof. | 10-13-2011 |
20120171279 | STRONGLY BOUND BASE-MODIFIED OLIGONUCLEOTIDES - The present invention provides compounds having a chelating moiety and an oligonucleotide sequence wherein the oligonucleotide includes one or more modified nucleobases, such as hydroxynucleobases. The disclosed compounds are suitable for antisense therapy. The chelating moiety can be complexed to an ion of a lanthanide metal. These compounds are efficient translation inhibitors of nucleic acids and have increased binding affinity for target nucleic acids. The invention also includes compositions and methods of using these compositions as antisense therapy. | 07-05-2012 |
20130030180 | Methods of Facilitating Neural Cell Survival Using GDNF Family Ligand (GFL) Mimetics or RET Signaling Pathway Activators - Disclosed are compounds and methods for treating neurological and other disorders by administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for GFRα receptor molecules, which can be mimetics of glial-derived neurotrophic factor (GDNF) family ligands (GFLs), GFRα/RET signaling pathway agonists, and/or direct RET agonists (activators). | 01-31-2013 |
20130274186 | NEURTURIN MOLECULES - Neurturin polypeptides which possess reduced heparin and heparan sulfate binding affinity but retain neurotrophic activity, nucleic acids which encode the neurturin variants and vectors and host cells which express the enhanced neurturin polypeptides. Use of the enhanced neurturin polypeptides, nucleic acids and host cells in the treatment or prevention of disease. | 10-17-2013 |
20140259192 | TRANSGENIC ANIMAL COMPRISING A DELETION OR FUNCTIONAL DELETION OF THE 3'UTR OF AN ENDOGENOUS GENE - The present invention relates to the fields of knockout (KO) animal production. The invention is directed to a transgenic KO animal comprising a heterozygous or homozygous deletion or functional deletion of the gene's native 3′ untranslated region (3′UTR) at least in one of its endogenous gene loci, wherein the disrupted endogenous gene is transcribed into an m RNA without its native 3′UTR. Instead, a 3′UTR of choice, knocked in by the experimenter, is transcribed into an m RNA. The 3′UTR KO animals provide a new approach to study gene function as they enable to overexpress the gene products what are negatively regulated via their 3′UTR-s exclusively in those cells that already transcribe the gene, thereby avoiding the misexpression problem present in the animals produced by conventional transgenesis methods. The invention is further directed to KO animals, in which the gene with deletion of 3′UTR is GDNF, NGF or BDNF. | 09-11-2014 |
20150020222 | NEUROTROPHIC FACTOR MANF AND USES THEREOF - The present invention generally relates to the field of treatment of neuronal disorders and more particularly to neurotrophic factor MANF and uses thereof. The present invention provides a pharmaceutical compound comprising MANF nucleic acid molecule, MANF protein or a functional fragment thereof for the treatment of a peripherial neuropathy including Alzheimer's disease, Parkinson's disease, epilepsy, drug addiction and ischemic brain injury. | 01-15-2015 |
20150141329 | NEURTURIN MOLECULES - Neurturin polypeptides which possess reduced heparin and heparan sulfate binding affinity but retain neurotrophic activity, nucleic acids which encode the neurturin variants and vectors and host cells which express the enhanced neurturin polypeptides. Use of the enhanced neurturin polypeptides, nucleic acids and host cells in the treatment or prevention of disease. | 05-21-2015 |
20150202263 | NEURTURIN MOLECULES - Neurturin polypeptides which possess reduced heparin and heparan sulfate binding affinity but retain neurotrophic activity, nucleic acids which encode the neurturin variants and vectors and host cells which express the enhanced neurturin polypeptides. Use of the enhanced neurturin polypeptides, nucleic acids and host cells in the treatment or prevention of disease. | 07-23-2015 |
Patent application number | Description | Published |
20090252707 | NOVEL EXPRESSION VECTORS AND USES THEREOF - A method for treating an HIV disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a DNA vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a DNA sequence encoding a nuclear-anchoring protein, where the nuclear-anchoring protein comprises: (i) a DNA binding domain which binds to a specific DNA binding sequence, and (ii) a functional domain of the Bovine Papilloma Virus Type 1 E2 protein, where the functional domain binds to a nuclear component; (b) a multimerized DNA sequence that forms a binding site for the nuclear anchoring protein; and (c) at least one expression cassette comprising a DNA sequence encoding a protein or peptide that stimulates an immune response specific to the protein or peptide; where the expression vector lacks an origin of replication functional in mammalian cells. | 10-08-2009 |
20100279416 | METHOD FOR INTRODUCING CHANGES INTO A EUKARYOTIC GENOME IN VIVO AND A KIT - The invention relates to a method for introducing changes into a eukaryotic genome in vivo wherein the HPV genome, which comprises HPV replication origin sequence, is used together with HPV early proteins in order to achieve DNA replication in vivo. There is also disclosed a kit for in vivo amplification, excision, translocation and/or inversion of a DNA sequence, which comprises a vector carrying HPV genome or a part of HPV genome including HPV replication origin sequence, and expression vector or vectors encoding HPV early proteins. | 11-04-2010 |
20110076760 | Viral expression plasmids for production of proteins, antibodies, enzymes, virus-like particles and for use in cell-based assays - This disclosure shows that the EBV FR-element comprised of EBNA1 multimeric binding sites can provide the stable maintenance replication function to the mouse polyomavirus (PyV) core origin plasmids in the presence of BPV-1 E2 protein and PyV large T-antigen (LT). | 03-31-2011 |
20110171255 | EXPRESSION VECTOR ENCODING ALPHAVIRUS REPLICASE AND THE USE THEREOF AS IMMUNOLOGICAL ADJUVANT - The present invention relates to an alphaviral replicase, especially Semliki Forest Virus replicase, or an expression vector encoding an alphaviral replicase, said alphaviral replicase comprising RNA dependent RNA polymerase activity, for use as an immune system modulating adjuvant. The alphaviral replicase may be used in the combination with a vaccine providing an adjuvant function therein, which when present therein will generate an additional boost to the immune response in the subject to whom this combination is administered as compared to when the vaccine alone is administered to a subject in need thereof. The aim of the present invention is to provide an efficient and easy to administer, species-independent adjuvant which will provide advantages to the adjuvants used together with vaccines today. | 07-14-2011 |
20130150262 | Method and Kit for Identifying Compounds Capable of Inhibiting Human Papilloma Virus Replication - This invention provides a method, kit and an in vitro system for identifying compounds capable of inhibiting Human Papilloma Virus replication at all the stages of viral replication cycle. The method, kit and in vitro system is applicable to all types of Human Papilloma Virus. The method enables high throughput screening of compounds inhibiting HPV replication in one or more phases of the cycle. | 06-13-2013 |
20130236958 | Viral expression plasmids for production of proteins, antibodies, enzymes, virus-like particles and for use in cell-based assays - This disclosure shows that the EBV FR-element comprised of EBNA1 multimeric binding sites can provide the stable maintenance replication function to the mouse polyomavirus (PyV) core origin plasmids in the presence of BPV-1 E2 protein and PyV large T-antigen (LT). | 09-12-2013 |
20140234361 | NOVEL EXPRESSION VECTORS AND USES THEREOF - A method for treating an HIV disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a DNA vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a DNA sequence encoding a nuclear-anchoring protein, where the nuclear-anchoring protein comprises: (i) a DNA binding domain which binds to a specific DNA binding sequence, and (ii) a functional domain of the Bovine Papilloma Virus Type 1 E2 protein, where the functional domain binds to a nuclear component; (b) a multimerized DNA sequence that forms a binding site for the nuclear anchoring protein; and (c) at least one expression cassette comprising a DNA sequence encoding a protein or peptide that stimulates an immune response specific to the protein or peptide; where the expression vector lacks an origin of replication functional in mammalian cells. | 08-21-2014 |